


## Amendments to the Claims:

The listing of claims will replace all prior versions and listings of claims in the application:

### **Listing of Claims:**

Claim 1 (original): A  $\delta$ -amino- $\gamma$ -hydroxy- $\omega$ -aryl-alkanoic acid amide compound of formula (I)



wherein

- $R^1$  is hydrogen, halogen, optionally halogenated alkyl, cycloalkyl, hydroxy, optionally halogenated alkoxy, cycloalkoxy, lower alkoxy-lower alkoxy or free or esterified or amidated carboxy-lower alkoxy or lower alkyl;
- $R^2$  is hydrogen, halogen, optionally halogenated lower alkyl, hydroxy, cycloalkyl, cycloalkoxy, optionally halogenated lower alkoxy-lower alkyl, optionally substituted lower alkoxy-lower alkyl, cycloalkoxy-lower alkyl; optionally lower alkanoylated, halogenated or sulfonylated hydroxy-lower alkoxy; amino-lower alkyl that is unsubstituted or substituted by lower alkyl, by lower alkanoyl and/or by lower alkoxycarbonyl, optionally hydrogenated heteroaryl-lower alkyl, amino-lower alkoxy that is substituted by lower alkyl, by lower alkanoyl and/or by lower alkoxycarbonyl; oxo-lower alkoxy, lower alkoxy, lower alkenyloxy, cycloalkoxy-lower alkoxy, lower alkoxy-lower alkoxy, lower alkoxy-lower alkenyl, lower alkenyloxy-lower alkoxy, lower alkoxy-lower alkenyloxy, lower alkenyloxy-lower alkyl, lower alkanoyl lower alkoxy, optionally S-oxidised lower alkylthio-lower alkoxy, lower alkylthio-(hydroxy)-lower alkoxy, aryl-lower alkoxy, aryl-lower alkyl, aryl-lower alkoxy, optionally hydrogenated heteroaryl-lower alkoxy, optionally hydrogenated heteroaryl-lower alkyl, cyano-lower alkoxy, cyano-lower alkyl, free or esterified or amidated carboxy-lower alkoxy or free or esterified or amidated carboxy-lower alkyl;
- $R^3$  and  $R^4$  are independently hydrogen, halogen, optionally halogenated lower alkyl, hydroxy, optionally halogenated lower alkoxy or cycloalkoxy, lower alkoxy-lower alkyl, cycloalkoxy-lower alkyl, hydroxy-lower alkyl, optionally S-oxidised lower alkylthio-lower alkyl, optionally hydrogenated heteroarylthio-lower alkyl, optionally hydrogenated heteroaryl-lower alkyl; amino-lower alkyl that is unsubstituted or *N*-mono- or *N,N*-di-lower alkylated, *N*-lower alkanoylated or *N*-lower alkanesulfonylated or *N,N*-disubstituted by

lower alkylene, by unsubstituted or *N'*-lower alkylated or *N'*-lower alkanoylated aza-lower alkylene, by oxa-lower alkylene or by optionally *S*-oxidised thia-lower alkylene, cyano-lower alkyl, free or esterified or amidated carboxy-lower alkyl, cycloalkyl, aryl, hydroxy, lower alkoxy, cycloalkoxy, lower alkoxy-lower alkoxy, cycloalkoxy-lower alkoxy, hydroxy-lower alkoxy, aryl-lower alkoxy, optionally halogenated lower alkoxy, optionally *S*-oxidised lower alkylthio-lower alkoxy, optionally hydrogenated heteroaryl-lower alkoxy, optionally hydrogenated heteroarylthio-lower alkoxy; amino-lower alkoxy that is unsubstituted or *N*-mono- or *N,N*-di-lower alkylated, *N*-lower alkanoylated or *N*-lower alkanesulfonylated or substituted by lower alkylene, by unsubstituted or *N'*-lower alkylated or *N'*-lower alkanoylated aza-lower alkylene, by oxa-lower alkylene or by optionally *S*-oxidised thia-lower alkylene, cyano-lower alkoxy or free or esterified or amidated carboxy-lower alkoxy; or

$R^4$  together with  $R_3$  is lower alkeneoxy, lower alkylenedioxy or a fused-on aryl, optionally hydrogenated heteroaryl or cycloalkyl ring;

*X* is methylene, hydroxymethylene, oxygen, optionally lower alkyl substituted nitrogen, optionally oxidized sulfur;

$R^5$  is lower alkyl or cycloalkyl;

$R^6$  is hydrogen, lower alkyl, hydroxy, alkoxy or halogen;

$R^7$  is unsubstituted or *N*-mono- or *N,N*-di-lower alkylated or *N*-lower alkanoylated amino;

$R^8$  is lower alkyl, lower alkenyl, cycloalkyl or aryl-lower alkyl;

$R^9$  is optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkyl-alkyl, cycloalkyl carboxamides, *N*-mono or *N,N*-dialkyl substituted cycloalkyl carboxamides, optionally substituted aryl-alkyl, optionally substituted aryloxy-aryl, optionally substituted heteroaryloxy-alkyl, free or aliphatically esterified or etherified hydroxy-lower alkyl; amino-lower alkyl that is unsubstituted or *N*-lower alkanoylated or *N*-mono- or *N,N*-di-lower alkylated or *N,N*-di-substituted by lower alkylene, by hydroxy-, lower alkoxy- or lower alkanoyloxy-lower alkylene, by unsubstituted or *N'*-lower alkanoylated or *N'*-lower alkylated aza-lower alkylene, by oxa-lower alkylene or by optionally *S*-oxidised thia-lower alkylene, free or esterified or amidated carboxy-lower alkyl, free or esterified or amidated dicarboxy-lower alkyl, free or esterified or amidated carboxy-(hydroxy)-lower alkyl, free or esterified or amidated carboxycycloalkyl-lower alkyl, cyano-lower alkyl, lower alkanesulfonyl-lower alkyl, unsubstituted or *N*-mono- or *N,N*-di-lower alkylated thiocarbamoyl-lower alkyl, unsubstituted or *N*-mono- or *N,N*-di-lower alkylated sulfamoyl-lower alkyl, or a heteroaryl radical bonded *via* a carbon atom and optionally hydrogenated and/or oxo-substituted, or lower alkyl substituted by a heteroaryl radical bonded *via* a carbon atom and optionally hydrogenated and/or oxo-substituted;

or a pharmaceutically acceptable salt thereof.

Claim 2 (original): A compound according to claim 1 wherein

R<sup>9</sup> is lower alkyl, optionally substituted cycloalkyl (alkyl, OH, alkoxy, alkoxy-alkyl, halogens), optionally substituted cycloalkyl-alkyl (OH, alkoxy, alkoxy-alkyl, halogens on cycloalkyl), cycloalkyl carboxamides, *N*- mono or *N,N*-dialkyl substituted cycloalkyl carboxamides, optionally substituted aryl-alkyl, free or aliphatically esterified or etherified hydroxy-lower alkyl; amino-lower alkyl that is unsubstituted or *N*-lower alkanoylated or *N*-mono- or *N,N*-di-lower alkylated or *N,N*-di-substituted by lower alkylene, by hydroxy-, lower alkoxy- or lower alkanoyloxy-lower alkylene, by unsubstituted or *N'*-lower alkanoylated or *N'*-lower alkylated aza-lower alkylene, by oxa-lower alkylene or by optionally *S*-oxidised thia-lower alkylene, free or esterified or amidated carboxy-lower alkyl, free or esterified or amidated dicarboxy-lower alkyl, free or esterified or amidated carboxy-(hydroxy)-lower alkyl, free or esterified or amidated carboxycycloalkyl-lower alkyl, cyano-lower alkyl, lower alkanesulfonyl-lower alkyl, unsubstituted or *N*-mono- or *N,N*-di-lower alkylated thiocarbamoyl-lower alkyl, unsubstituted or *N*-mono- or *N,N*-di-lower alkylated sulfamoyl-lower alkyl, or a heteroaryl radical bonded *via* a carbon atom and optionally hydrogenated and/or oxo-substituted, or lower alkyl substituted by a heteroaryl radical bonded *via* a carbon atom and optionally hydrogenated and/or oxo-substituted;

or a pharmaceutically acceptable salt thereof.

Claim 3 (original): A compound according to claim 2 wherein

R<sup>1</sup> and R<sup>4</sup> are hydrogen;

R<sup>2</sup> is lower alkoxy-lower alkoxy;

R<sup>3</sup> is halogen or mono, di or tri-halo-substituted alkyl;

or a pharmaceutically acceptable salt thereof.

Claim 4 (original): A compound according to claim 3 wherein the halogen/halo is fluorine or chlorine;

or a pharmaceutically acceptable salt thereof.

Claim 5 (original): A compound according to claim 4 wherein

R<sup>3</sup> is fluorine or trifluoromethyl;

or a pharmaceutically acceptable salt thereof.

Claim 6 (original): A compound according to claim 5 wherein R<sup>2</sup> is in the meta position and R<sup>3</sup> is in the para position;

or a pharmaceutically acceptable salt thereof.

Claim 7 (original): A compound according to claim 5 wherein  $R^3$  is in the ortho position;  
or a pharmaceutically acceptable salt thereof.

Claim 8 (original): A compound according to claim 5 wherein  $R^3$  is in the meta position;  
or a pharmaceutically acceptable salt thereof.

Claim 9 (original): A compound according to claim 2 wherein  $R^2$  is in the meta position and is lower alkoxy-lower alkoxy optionally substituted by halogen(s);  
or a pharmaceutically acceptable salt thereof.

Claim 10 (original): A compound according to claim 9 wherein the halogen(s) is fluorine or chlorine;  
or a pharmaceutically acceptable salt thereof.

Claim 11 (original): A compound according to claim 10 wherein the halogen(s) is fluorine;  
or a pharmaceutically acceptable salt thereof.

Claim 12 (original): A compound according to claim 9 wherein  $R^3$  is lower alkoxy substituted by halogen(s);  
or a pharmaceutically acceptable salt thereof.

Claim 13 (original): A compound according to claim 12 wherein the halogen(s) is fluorine or chlorine;  
or a pharmaceutically acceptable salt thereof.

Claim 14 (original): A compound according to claim 13 wherein the halogen(s) is fluorine;  
or a pharmaceutically acceptable salt thereof.


Claim 15 (original): A compound according to claim 9 wherein  $R^3$  is in the para position;  
or a pharmaceutically acceptable salt thereof.

Claim 16 (original): A compound according to claim 15 wherein  $R^3$  is methoxy;  
or a pharmaceutically acceptable salt thereof.

Claim 17 (original): A compound according to claim 15 wherein  $R^3$  is trifluoro-methoxy;  
or a pharmaceutically acceptable salt thereof.

Claim 18 (original): A compound according to claim 1 wherein  
 $R^3$  is located at the para position and is halogen;  
or a pharmaceutically acceptable salt thereof.

Claim 19 (original): A  $\delta$ -amino- $\gamma$ -hydroxy- $\omega$ -aryl-alkanoic acid amide compound according to claim 1 having formula (Ia)



wherein

$R^1$  is hydrogen, halogen, optionally halogenated alkyl, cycloalkyl, hydroxy, optionally halogenated alkoxy, cycloalkoxy, lower alkoxy-lower alkoxy or free or esterified or amidated carboxy-lower alkoxy or lower alkyl;

$R^2$  is hydrogen, halogen, optionally halogenated lower alkyl, hydroxy, cycloalkyl, cycloalkoxy, optionally halogenated lower alkoxy-lower alkyl, optionally substituted lower alkoxy-lower alkoxy, cycloalkoxy-lower alkyl; optionally lower alkanoylated, halogenated or sulfonylated hydroxy-lower alkoxy; amino-lower alkyl that is unsubstituted or substituted by lower alkyl, by lower alkanoyl and/or by lower alkoxycarbonyl; optionally hydrogenated heteroaryl-lower alkyl; amino-lower alkoxy that is substituted by lower alkyl, by lower alkanoyl and/or by lower alkoxycarbonyl; oxo-lower alkoxy, lower alkoxy, cycloalkoxy, lower alkenyloxy, cycloalkoxy-lower alkoxy, lower alkoxy-lower alkenyl, lower alkenyloxy-lower alkoxy, lower alkoxy-lower alkenyloxy, lower alkenyloxy-lower alkyl, lower alkanoyl-lower alkoxy, optionally S-oxidised lower alkylthio-lower alkoxy, lower alkylthio-(hydroxy)-lower alkoxy, aryl-lower alkoxy, aryl-lower alkyl, aryl-lower alkoxy, optionally hydrogenated heteroaryl-lower alkoxy, optionally hydrogenated hetero-aryl-lower alkyl, cyano-lower alkoxy, cyano-lower alkyl, free or esterified or amidated carboxy-lower alkoxy or free or esterified or amidated carboxy-lower alkyl;

$R^3$  and  $R^4$  are independently hydrogen, halogen, optionally halogenated lower alkyl, hydroxy, optionally halogenated lower alkoxy or cycloalkoxy, lower alkoxy-lower alkyl, cycloalkoxy-lower alkyl, hydroxy-lower alkyl, optionally S-oxidised lower alkylthio-lower alkyl, optionally hydrogenated heteroarylthio-lower alkyl, optionally hydrogenated hetero-aryl-lower alkyl; amino-lower alkyl that is unsubstituted or *N*-mono- or *N,N*-di-lower alkyl-ated, *N*-lower alkanoylated or *N*-lower alkanesulfonylated or *N,N*-disubstituted by lower alkylene, by unsubstituted or *N'*-lower alkylated or *N'*-lower alkanoylated aza-lower alkylene, by oxa-lower alkylene or by optionally S-oxidised thia-lower alkylene; cyano--lower alkyl, free or esterified or amidated carboxy-lower alkyl, cycloalkyl, aryl, hydroxy, lower alkoxy, cycloalkoxy, lower alkoxy-lower alkoxy, cycloalkoxy-lower alkoxy, hydroxy-

lower alkoxy, aryl-lower alkoxy, optionally halogenated lower alkoxy, optionally S-oxidised lower alkylthio-lower alkoxy, optionally hydrogenated heteroaryl-lower alkoxy, optionally hydrogenated heteroarylthio-lower alkoxy; amino-lower alkoxy that is unsubstituted or *N*-mono- or *N,N*-di-lower alkylated, *N*-lower alkanoylated or *N*-lower alkanesulfonylated or substituted by lower alkylene, by unsubstituted or *N'*-lower alkylated or *N'*-lower alkanoylated aza-lower alkylene, by oxalower alkylene or by optionally S-oxidised thia-lower alkylene; cyano-lower alkoxy or free or esterified or amidated carboxy-lower alkoxy; or

R<sup>4</sup> together with R<sub>3</sub> is lower alkeneoxy, alkylenedioxy or a fused-on aryl, optionally hydrogenated heteroaryl or cycloalkyl ring;

X is methylene, hydroxymethylene, oxygen, optionally lower alkyl substituted nitrogen or optionally oxidized sulfur;

R<sup>5</sup> is lower alkyl or cycloalkyl;

R<sup>6</sup> is hydrogen, lower alkyl, hydroxy, alkoxy or halogen;

R<sup>7</sup> is unsubstituted or *N*-mono- or *N,N*-di-lower alkylated or *N*-lower alkanoylated amino;

R<sup>8</sup> is lower alkyl, lower alkenyl, cycloalkyl or aryl-lower alkyl;

R<sup>9</sup> is optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkyl-alkyl, cycloalkyl carboxamides, *N*-mono or *N,N*-dialkyl substituted cycloalkyl carboxamides, optionally substituted aryl-alkyl, optionally substituted aryloxy-aryl, optionally substituted heteroaryloxy-alkyl, free or aliphatically esterified or etherified hydroxy-lower alkyl; amino-lower alkyl that is unsubstituted or *N*-lower alkanoylated or *N*-mono- or *N,N*-di-lower alkylated or *N,N*-di-substituted by lower alkylene, by hydroxy-, lower alkoxy- or lower alkanoyloxy-lower alkylene, by unsubstituted or *N'*-lower alkanoylated or *N'*-lower alkylated aza-lower alkylene, by oxa-lower alkylene or by optionally S-oxidised thia-lower alkylene, free or esterified or amidated carboxy-lower alkyl, free or esterified or amidated dicarboxy-lower alkyl, free or esterified or amidated carboxy-(hydroxy)-lower alkyl, free or esterified or amidated carboxycycloalkyl-lower alkyl, cyano-lower alkyl, lower alkanesulfonyl-lower alkyl, unsubstituted or *N*-mono- or *N,N*-di-lower alkylated thiocarbamoyl-lower alkyl, unsubstituted or *N*-mono- or *N,N*-di-lower alkylated sulfamoyl-lower alkyl, or a heteroaryl radical bonded *via* a carbon atom and optionally hydrogenated and/or oxo-substituted, or lower alkyl substituted by a heteroaryl radical bonded *via* a carbon atom and optionally hydrogenated and/or oxo-substituted;

or a pharmaceutically acceptable salt thereof.

Claim 20 (original): A compound according to claim 19 wherein

R<sup>9</sup> is cycloalkyl substituted with alkyl, hydroxy, alkoxy, alkoxy-alkoxy or halogens; cycloalkyl-alkyl optionally substituted with alkyl, hydroxy, alkoxy, alkoxy-alkoxy or halogens on cycloalkyl or halogens on alkyl or halogens on alkoxy; cycloalkyl carboxamides; *N*-mono or *N,N*-dialkyl substituted cycloalkyl carboxamides; or optionally substituted aryl-alkyl;

or a pharmaceutically acceptable salt thereof.

Claim 21 (original): A compound according to claim 19 wherein

R<sup>9</sup> is hydrogen; halogenated alkyl; optionally substituted aryl-alkyl, optionally substituted aryloxy-alkyl, cycloalkyl substituted by 1 to 3 substituents selected from the group consisting of alkenyl, alkynyl, halo, hydroxy, alkoxy, alkoxy-alkoxy, alkylthio, arylthio, aryl-alkoxy, carbamoyl, sulfamoyl, sulfonyl, optionally substituted amino, cyano, carboxy, alkoxycarbonyl, aryl, aryloxy, heterocyclyl or alkyl optionally substituted by amino, halo, hydroxy, alkoxy, carboxy, alkoxycarbonyl, carbamoyl or heterocyclyl; or optionally substituted cycloalkyl-alkyl;

or a pharmaceutically acceptable salt thereof.

Claim 22 (original): A compound according to claim 21 wherein

R<sup>1</sup> is hydrogen;

R<sup>2</sup> is C<sub>1</sub>-C<sub>4</sub> alkoxy – C<sub>1</sub>-C<sub>4</sub> alkoxy or C<sub>1</sub>-C<sub>4</sub> alkoxy – C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sup>3</sup> is C<sub>1</sub>-C<sub>4</sub> alkyl or C<sub>1</sub>-C<sub>4</sub> alkoxy;

R<sup>4</sup> is hydrogen;

X is methylene;

R<sup>5</sup> is lower alkyl;

R<sup>6</sup> is hydrogen;

R<sup>7</sup> is unsubstituted amino;

R<sup>8</sup> is branched C<sub>3</sub>-C<sub>4</sub> alkyl;

R<sup>9</sup> is optionally substituted cycloalkyl-alkyl;

or a pharmaceutically acceptable salt thereof.

Claim 23 (original): A compound according to claim 22 wherein

R<sup>2</sup> is 3-methoxypropyloxy;

R<sup>3</sup> is methoxy;

R<sup>5</sup> is isopropyl;

R<sup>8</sup> is isopropyl;

or a pharmaceutically acceptable salt thereof.

Claim 24 (original): The compound of claim 21 wherein

R<sup>1</sup> is hydrogen;

R<sup>2</sup> is C<sub>1</sub>-C<sub>4</sub> alkoxy – C<sub>1</sub>-C<sub>4</sub> alkoxy or C<sub>1</sub>-C<sub>4</sub> alkoxy – C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sup>3</sup> is C<sub>1</sub>-C<sub>4</sub> alkyl or C<sub>1</sub>-C<sub>4</sub> alkoxy;

R<sup>4</sup> is hydrogen;

X is methylene;

R<sup>5</sup> is lower alkyl;

R<sup>6</sup> is hydrogen;

R<sup>7</sup> is unsubstituted amino;

R<sup>8</sup> is branched C<sub>3</sub>-C<sub>4</sub> alkyl;

R<sup>9</sup> is optionally substituted aryl-alkyl; or

a pharmaceutically acceptable salt thereof.

Claim 25 (original): A compound according to claim 24 wherein

R<sup>2</sup> is 3-methoxypropyloxy;

R<sup>3</sup> is methoxy;

R<sup>5</sup> is isopropyl;

R<sup>8</sup> is isopropyl;

or a pharmaceutically acceptable salt thereof.

Claim 26 (original): The compound of claim 24 wherein aryl-alkyl is alkyl substituted with phenyl;

or a pharmaceutically acceptable salt thereof.

Claim 27 (original): The compound of claim 26 wherein aryl-alkyl is methyl substituted with phenyl.

Claim 28 (original): A compound according to claim 27 wherein

R<sup>2</sup> is 3-methoxypropyloxy;

R<sup>3</sup> is methoxy;



R<sup>5</sup> is isopropyl;

R<sup>8</sup> is isopropyl;

or a pharmaceutically acceptable salt thereof.

Claim 29 (currently amended): A method for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders which method comprises administering a therapeutically effective amount of the compound of ~~claim 4~~ formula (1) to a warm-blooded animal in need thereof.

Claim 30 (currently amended): A pharmaceutical composition comprising the compound of ~~claim 4~~ formula (1) and one or more pharmaceutically acceptable excipient(s).

Claim 31 (currently amended): A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 in combination with a therapeutically effective amount of an anti-diabetic ~~agents~~ agent, a hypolipidemic agent, an anti-obesity agent or an anti-hypertensive agent.

Claim 32 (currently amended): A pharmaceutical composition according to claim 30 ~~or 34~~ for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.

Claim 33 - 36 (cancelled):

Claim 37 (original): A compound according to claim 1, for use as a medicament.

Claim 38 (new): A pharmaceutical composition according to claim 31 for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels,

restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.